Publications

Liste des publications de l'année 2020

Articles

Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group.

André T, Vernerey D, Im SA, et al. Bevacizumab as adjuvant treatment of colon cancer

Ann Oncol. 2020;31(2):246-256. doi:10.1016/j.annonc.2019.12.006

Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patients_

Aparicio T, Henriques J, Manfredi S

Int J Cancer. 2020;147(4):967-977. doi:10.1002/ijc.32860

Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial

Boilève A, Hilmi M, Gougis P, Cohen R, Rousseau B, Blanc JF, Ben Abdelghani M, Castanié H, Dahan L, Tougeron D, Metges JP, Tournigand C, Garcia-Larnicol ML, Vernerey D, Turpin A, Neuzillet C.

Eur J Cancer. 2020 Dec 3;143:55-63. doi: 10.1016/j.ejca.2020.10.027. Epub ahead of print. PMID: 33279854

Understanding the Prognostic Value of Primary Tumor Location and KRAS in Metastatic Colorectal Cancer: A Post Hoc Analysis of the OPTIMOX3 DREAM Phase III Stud

Chibaudel B, André T, Tournigand C,

Clin Colorectal Cancer. 2020;S1533-0028(20)30035-9. doi:10.1016/j.clcc.2020.02.012

Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer

Chibaudel B, Henriques J, Rakez M, Brenner B, Kim TW, Martinez-Villacampa M, Gallego-Plazas J, Cervantes A, Shim K, Jonker D, Guerin-Meyer V, Mineur L, Banzi C, Dewdney A, Dejthevaporn T, Bloemendal HJ, Roth A, Moehler M, Aranda E, Van Cutsem E, Tabernero J, Schmoll HJ, Hoff PM, André T, de Gramont A.

JAMA Netw Open. 2020 Oct 1;3(10):e2020425. doi: 10.1001/jamanetworkopen.2020.20425. PMID: 33074326; PMCID: PMC7573695

Patients atteints d’un cancer gastrique localisé MSI/dMMR, pas de chimiothérapie mais une immunothérapie périopératoire : l’essai de phase II GERCOR NEONIPIGA vient d’être ouvert au recrutement [Localized MSI/dMMR gastric cancer patients, perioperative im

Cohen R, Pudlarz T, Garcia-Larnicol ML

Bull Cancer. 2020;107(4):438-446. doi:10.1016/j.bulcan.2019.11.016

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study.

Cohen R, Bennouna J, Meurisse A, Tournigand C, De La Fouchardière C, Tougeron D, Borg C, Mazard T, Chibaudel B, Garcia-Larnicol ML, Svrcek M, Vernerey D, Menu Y, André T

J Immunother Cancer. 2020 Nov;8(2):e001499. doi: 10.1136/jitc-2020-001499. PMID: 33148693.

Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR).

de Mestier L, Lepage C, Baudin E

Dig Liver Dis. 2020;52(5):473-492. doi:10.1016/j.dld.2020.02.011

Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR). J Clin Oncol

Delattre JF, Cohen R, Henriques J

J Clin Oncol. 2020;38(15):1702-1710. doi:10.1200/JCO.19.01960

COVID-19 epidemic: Proposed alternatives in the management of digestive cancers: A French intergroup clinical point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR).

Di Fiore F, Bouché O, Lepage C

Dig Liver Dis. 2020;52(6):597-603. doi:10.1016/j.dld.2020.03.031

Nutrition and physical activity professional education in gastrointestinal oncology: a national multidisciplinary survey

Hilmi M, Pellat A, Benoit O

BMJ Support Palliat Care. 2020;10(3):324-330. doi:10.1136/bmjspcare-2020-002342

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial

Kim S, Buecher B, André T

BMC Cancer. 2020;20(1):352. Published 2020 Apr 25. doi:10.1186/s12885-020-06841-1

Nutrition and physical activity professional education in gastrointestinal oncology: a national multidisciplinary survey

Hilmi M, Pellat A, Benoit O

BMJ Support Palliat Care. 2020;10(3):324-330. doi:10.1136/bmjspcare-2020-002342

Impact of the IDEA Collaboration Study Results on Clinical Practice in France for Patients With Stage III Colon Cancer: A National GERCOR - PRODIGE Survey. Clin Colorectal Cancer

Ouali K, Turpin A, Neuzillet C, Rousseau B, Garcia-Larnicol ML, Tournigand C, Samalin E, Taieb J, André T, Cohen R

Clin Colorectal Cancer. 2020 Nov 14:S1533-0028(20)30158-4. doi: 10.1016/j.clcc.2020.11.004. Epub ahead of print. PMID: 33281064.

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study

Pagès F, André T, Taieb J

Ann Oncol. 2020;31(7):921-929. doi:10.1016/j.annonc.2020.03.310

The consensus Immunoscore in phase 3 clinical trials; potential impact on patient management decisions

Pagès F, Taieb J, Laurent-Puig P, Galon J

Oncoimmunology. 2020 Aug 28;9(1):1812221.

A comprehensive overview of promising biomarkers in stage II colorectal cancer

Parent P, Cohen R, Rassy E

Cancer Treat Rev. 2020;88:102059. doi:10.1016/j.ctrv.2020.102059

Fong's Score in the Era of Modern Perioperative Chemotherapy for Metastatic Colorectal Cancer: A Post Hoc Analysis of the GERCOR-MIROX Phase III Trial

Makhloufi S, Turpin A, El Amrani M

Chemotherapy for Metastatic Colorectal Cancer: A Post Hoc Analysis of the GERCOR-MIROX Phase III Trial. Ann Surg Oncol. 2020;27(3):877-885. doi:10.1245/s10434-019-07976-7

Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database

Salem ME, Yin J, Goldberg RM

Ann Oncol. 2020;31(4):480-486. doi:10.1016/j.annonc.2019.12.007

A new prognostic and predictive tool for shared decision making in stage III colon cancer

Sobrero AF, Puccini A, Shi Q

Eur J Cancer. 2020;138:182-188. doi:10.1016/j.ejca.2020.07.031

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

Lièvre A, Turpin A, Ray-Coquard I, Le Malicot K, Thariat J, Ahle G, Neuzillet C, Paoletti X, Bouché O, Aldabbagh K, Michel P, Debieuvre D, Canellas A, Wislez M, Laurent L, Mabro M, Colle R, Hardy-Bessard AC, Mansi L, Colomba E, Bourhis J, Gorphe P, Pointreau Y, Idbaih A, Ursu R, Di Stefano AL, Zalcman G, Aparicio T

Lièvre A, Turpin A, Ray-Coquard I, Le Malicot K, Thariat J, Ahle G, Neuzillet C, Paoletti X, Bouché O, Aldabbagh K, Michel P, Debieuvre D, Canellas A, Wislez M, Laurent L, Mabro M, Colle R, Hardy-Bessard AC, Mansi L, Colomba E, Bourhis J, Gorphe P, P

Management of digestive cancers during the COVID-19 second wave: A French intergroup point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR).

Tougeron D, Michel P, Lièvre A, Ducreux M, Gaujoux S, Guiu B, Huguet F, Lecomte T, Lepage C, Louvet C, Maggiori L, Mariani P, Aparicio T, Bouché O

Dig Liver Dis. 2020 Dec 16:S1590-8658(20)31050-1. doi: 10.1016/j.dld.2020.11.029. Epub ahead of print. PMID: 33341421

Abstracts

Impact of antibiotics (ATB) on the recurrence of resected colorectal cancer (CRC): Results of EVADER-1 a nation-wide pharmacoepidemiologic study

Benoit Rousseau, Marc Hilmi, Ines Khati, Anthony Turpin, Antoine Andremont, Charles Burdet, Nathalie Grall, Joana Vidal, Philippe Jean Bousquet, Christine Le Bihan

Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 4106-4106.

Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Dur

Alberto F. Sobrero, Thierry Andre, Jeffrey A Meyerhardt, Axel Grothey, Timothy Iveson, Takayuki Yoshino, Ioannis Sougklakos, Jeffrey P. Meyers, Roberto Labianca, Mark P. Saunders, Dewi Vernerey, Takeharu Yamanaka, Ioannis Boukovinas, Eiji Oki, Vassilis Georgoulias, Valter Torri, Andrea Harkin, Julien Taieb, Anthony Frank Shields, Qian Shi

J Clin Oncol 38: 2020 (suppl; abstr 4004) Abstract 4004

FOLFIRINOX de-escalation in advanced pancreatic cancer : a multicenter real-life study

Dewi Vernerey, Aurelia Meurisse, Pascal Hammel, Cindy Neuzillet, Christophe Borg, Anthony Turpin.

Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 4639-4639

RECIST and iRECIST criteria for the evaluation of nivolumab + ipilimumab combination in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Results of the GERCOR NIPICOL phase II st

Romain Cohen, Jaafar Bennouna, Julie Henriques, Christophe Tournigand, Christelle De La Fouchardiere, David Tougeron, Christophe Borg, Thibault Mazard, Benoist Chibaudel, Marie-Line Garcia-Larnicol, Magali Svrcek, Dewi Vernerey, Yves Menu, Thierry Andre

Journal of Clinical Oncology 38, no. 4_suppl (February 01, 2020) Abst 101.

Immunoscore as a parameter predicting time to recurrence and disease-free survival in T4N0 stage II colon cancer patients.

Jerome Galon, Fabienne Hermitte, Bernhard Mlecnik, Alessandro Lugli, Carlo Bruno Bifulco, Iris D. Nagtegaal, Arndt Hartmann, Florence Marliot, Marc Van Den Eynde, Michael H. A. Roehrl, Pamela S Ohashi, Eva Zavadova, Toshihiko Torigoe, Prabhudas S. Patel, Yili Wang, Yutaka Kawakami, Francesco Marincola, Paolo Antonio Ascierto, Bernard A. Fox, Franck Pages

Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 4105-4105.

Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database

Zhaohui Jin, Jesse G. Dixon, Hiral D. Parekh, Steven R Alberts, Greg Yothers, Carmen Joseph Allegra, Rachel Kerr, Daniel G. Haller, Aimery De Gramont, Takayuki Yoshino, Eric Van Cutsem, Chris Twelves, Julien Taieb, Leonard B. Saltz, Jean-François Seitz, Thierry Andre, Amit Mahipal, Richard M. Goldberg, Qian Shi, Thomas J. George

J Clin Oncol 38: 2020

Posters

Impact of antibiotics (ATB) on the recurrence of resected colorectal cancer (CRC): Results of EVADER-1 a nation-wide pharmacoepidemiologic study

Benoit Rousseau, Marc Hilmi, Ines Khati, Anthony Turpin, Antoine Andremont, Charles Burdet, Nathalie Grall, Joana Vidal, Philippe Jean Bousquet, Christine Le Bihan

Poster 98

RECIST and iRECIST criteria for the evaluation of nivolumab + ipilimumab combination in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Results of the GERCOR NIPICOL phase II st

Romain Cohen, Jaafar Bennouna, Julie Henriques, Christophe Tournigand, Christelle De La Fouchardiere, David Tougeron, Christophe Borg, Thibault Mazard, Benoist Chibaudel, Marie-Line Garcia-Larnicol, Magali Svrcek, Dewi Vernerey, Yves Menu, Thierry Andre

The American Society of Clinical Oncology (ASCO) 2020 meeting

Immunoscore as a parameter predicting time to recurrence and disease-free survival in T4N0 stage II colon cancer patients

Jerome Galon, Fabienne Hermitte, Bernhard Mlecnik, Alessandro Lugli, Carlo Bruno Bifulco, Iris D. Nagtegaal, Arndt Hartmann, Florence Marliot, Marc Van Den Eynde, Michael H. A. Roehrl, Pamela S Ohashi, Eva Zavadova, Toshihiko Torigoe, Prabhudas S. Patel, Yili Wang, Yutaka Kawakami, Francesco Marincola, Paolo Antonio Ascierto, Bernard A. Fox, Franck Pages

Poster 97

CONTACT GERCOR

GERCOR
151 Rue du Faubourg Saint-Antoine
75011 Paris
Téléphone : +33 1 40 29 85 00
Télécopie : +331 40 29 85 00
Email : gercor@gercor.com.fr